What question did this study set out to answer?

This study aimed to create a whole-blood transcriptomic framework to derive a compact activity score for systemic lupus erythematosus (SLE).

June 10, 2026GenesOpen Access

A Staged Whole-Blood Transcriptomic Framework Identifies a Compact Myeloid–Lymphoid Activity Score in Systemic Lupus Erythematosus

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial identifies myeloid-lymphoid activity score in systemic lupus erythematosus, suggesting potential for clinical evaluation.

This study aimed to create a whole-blood transcriptomic framework to derive a compact activity score for systemic lupus erythematosus (SLE).
Organized public whole-blood transcriptome cohorts into discovery, validation, and single-cell layers.
Conducted BloodGen3 profiling with 233 samples, including 170 SLE patients and 63 controls.
Used reverse transcription quantitative PCR and flow cytometry for validation of findings.
Identified two whole-blood endotypes based on lymphoid versus myeloid/neutrophil activity.
The final activity score discriminated SLE from healthy controls with an AUC of 0.838.
The score also distinguished high from low/moderate disease activity with an AUC of 0.719.

Zhang et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial identifies myeloid-lymphoid activity score in systemic lupus erythematosus, suggesting potential for clinical evaluation.